Purchase this article with an account.
L.K. Blanco, O. Baca, R. Velasco, D. Viggiano, A. Babayan, J. Velazquez; Autologous Serum in High Risk Penetrating Keratoplasty Patients . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1284.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of topical autologous serum in the treatment of patients who underwent high risk penetrating keratoplasty (PKP)
We included patients with high risk factors for graft rejection who underwent PKP from March to October 2005. Autologous Serum was obtained from a 20 mililiter of blood sample, centrifuged and diluted according to Tsubota's technique. Six test tubes with 1 ml each were kept frozen at –70 °C and every week one of them unfrozen diluted with BSS and administered to the patient. The study group was treated with 20% diluted autologous serum eyedrops 4 times a day in addition to steroid therapy since the first day postoperative. PKP technique was with separate stitches Epithelial characteristics, pachometry (optical), presence of vascularization (grade 1 vessels overcome the limbus, grade 2 between suture and donor edge, grade 3 overcome donor edge, grade 4 invasion of corneal graft), uncorrected visual acuity, intraocular pressure, edema , pain , hyperemia were reported preoperative and postoperative every week for 6 months. Time and presence of rejection was recorded.
We included 6 patients, mean follow–up time was 20 weeks (range 15–22). Two weeks after surgery, 3 cases had intact and clear epithelial layer and 3 had mild punctuate keratitis. Only one case had vascularization grade 2, the remaining cases had no vascularization. Mean first week postoperative pachometry was 600 µ and 550 µ at 6 month postoperatively in 5 cases. Five of the six patients responded well to treatment (83.3%) and only one patient (16.6%) had graft rejection at 7th week after surgery. No side effects were noted in any of the treated patients
Autologous serum application is a safe and efficient way to provide a good ocular surface which may contribute to decrease the incidence of graft failure during the first 6 months of follow–up.
This PDF is available to Subscribers Only